Ishara Investments LP

Fundamental concentrated ★Signal healthcare specialist (100%) CIK 2111609
Long book
$99.0M
Q1 2026
Positions
36
Top-10 weight
51%
concentration
Last quarter
+21.4%
SPY +14.8%
Turnover
65%
of book per quarter

Strategy in plain words

auto-generated from filings

Ishara Investments LP is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $99.0M US long book across 36 positions.

The portfolio is concentrated: the top 10 names carry 51% of the portfolio. Turnover is high — positions rotate quickly, so individual names matter less than the process. Current anchor positions: PRAXIS PRECISION MEDICINES I, AXSOME THERAPEUTICS INC, XERIS BIOPHARMA HOLDINGS INC, KALVISTA PHARMACEUTICALS INC, AMICUS THERAPEUTICS INC.

We rate its filings as signal-bearing: position changes reflect genuine views.

Implied long-book return vs S&P 500

methodology: positions priced quarterly, no shorts/options
Fund long book S&P 500
Q4 2025
+0.8%
Q1 2026
+21.4%

Sector allocation

Healthcare
88%
Other
12%

Long book by quarter

$85.9M
Q4 2025
$99.0M
Q1 2026

What does Ishara Investments own?

Q1 2026 13F
CompanySectorSharesValue% of bookChange
PRAX PRAXIS PRECISION MEDICINES IHealthcare22.6K$7.3M7.3%-43.6%
AXSM AXSOME THERAPEUTICS INCHealthcare41.0K$6.9M7.0%New
XERS XERIS BIOPHARMA HOLDINGS INCHealthcare1.0M$5.9M6.0%+28.1%
4XC1 KALVISTA PHARMACEUTICALS INC276.8K$5.6M5.6%New
AM6 AMICUS THERAPEUTICS INC369.0K$5.3M5.4%+2.5%
BMRN BIOMARIN PHARMACEUTICAL INCHealthcare82.0K$4.6M4.7%-18.0%
VSTM VERASTEM INCHealthcare820.0K$4.3M4.4%+203.7%
RARE ULTRAGENYX PHARMACEUTICAL INHealthcare174.3K$3.7M3.7%+248.5%
ARWR ARROWHEAD PHARMACEUTICALS INHealthcare55.4K$3.5M3.5%New
PCVX VAXCYTE INCHealthcare57.4K$3.3M3.4%+14.8%
VERA VERA THERAPEUTICS INCHealthcare82.0K$3.3M3.3%New
TVTX TRAVERE THERAPEUTICS INCHealthcare110.7K$3.3M3.3%New
MLTX MOONLAKE IMMUNOTHERAPEUTICSHealthcare174.3K$3.2M3.3%New
ZNTL ZENTALIS PHARMACEUTICALS INCHealthcare1.2M$2.9M2.9%-6.8%
SRRK SCHOLAR ROCK HOLDING CORPHealthcare57.4K$2.8M2.8%New
ACAD ACADIA PHARMACEUTICALS INCHealthcare123.0K$2.7M2.8%-23.1%
ARDX ARDELYX INCHealthcare451.0K$2.7M2.7%New
MLYS MINERALYS THERAPEUTICS INCHealthcare82.0K$2.2M2.2%New
CPRX CATALYST PHARMACEUTICALS INCHealthcare82.0K$2.0M2.1%New
SION SIONNA THERAPEUTICS INCHealthcare49.2K$2.0M2.0%New
CTNM CONTINEUM THERAPEUTICS INC-AHealthcare142.0K$1.9M1.9%New
ALNY ALNYLAM PHARMACEUTICALS INCHealthcare5.1K$1.7M1.7%New
LGND LIGAND PHARMACEUTICALSHealthcare8.2K$1.6M1.7%New
EWTX EDGEWISE THERAPEUTICS INCHealthcare49.2K$1.5M1.6%-15.2%
IMTX IMMATICS NVHealthcare153.8K$1.5M1.5%+92.2%
LXRX LEXICON PHARMACEUTICALS INCHealthcare902.0K$1.4M1.4%+2.5%
BEAM BEAM THERAPEUTICS INCHealthcare57.4K$1.4M1.4%+14.8%
ORIC ORIC PHARMACEUTICALS INCHealthcare102.5K$1.3M1.3%-35.9%
NAMS NEWAMSTERDAM PHARMA CO NVHealthcare36.9K$1.2M1.2%+23.0%
ANNX ANNEXON INCHealthcare174.3K$965K1.0%-76.8%
IDYA IDEAYA BIOSCIENCES INCHealthcare24.6K$820K0.8%New
PTCT PTC THERAPEUTICS INCHealthcare10.3K$698K0.7%-71.5%
GOSS GOSSAMER BIO INCHealthcare820.0K$269K0.3%New

13F filing history

PeriodFormFiledEntriesReported valueFlagsSource
Q1 202613F-HRMay 15, 202637$105.6M canonicalSEC ↗
Q4 202513F-HRFeb 17, 202638$87.5M canonicalSEC ↗